Transcatheter intraarterial therapies: Rationale and overview

Robert J. Lewandowski, Jean Francois Geschwind, Eleni Liapi, Riad Salem

Research output: Contribution to journalReview articlepeer-review

174 Scopus citations


Transcatheter intraarterial therapies have proved valuable in the battle against primary and secondary hepatic malignancies. The unique aspects of all such therapies are their reduced toxicity profiles and highly effective tumor responses. These unique characteristics coupled with their minimally invasive nature provide an attractive therapeutic option in patients who may have previously had few alternatives. The concept of all catheter-based intraarterial therapies is to selectively deliver anticancer treatment to tumor(s). These therapies, which include transarterial embolization, intraarterial chemoinfusion, transarterial chemoembolization with or without drug-eluting beads, and radioembolization with use of yttrium 90, inflict lethal insult to tumors while preserving normal hepatic parenchyma. This is possible because hepatic neoplasms preferentially derive their blood supply from an arterial source while the majority of noncancerous liver is supplied by the portal vein. As part of the interventional oncology review series, in this article we describe the rationale behind each of these transcatheter therapies and provide a review of the existing medical literature.

Original languageEnglish (US)
Pages (from-to)641-657
Number of pages17
Issue number3
StatePublished - Jun 2011

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Transcatheter intraarterial therapies: Rationale and overview'. Together they form a unique fingerprint.

Cite this